Literature DB >> 9080399

Perforins in human cytolytic cells: the effect of age.

E Mariani1, S Sgobbi, A Meneghetti, M Tadolini, A Tarozzi, M Sinoppi, L Cattini, A Facchini.   

Abstract

The ageing process is associated with a progressive increase in the number of circulating NK cells, together with a decreased lytic activity per cell. A similar decrease in activity was also found for CD8 lymphocytes. Cytotoxic T- and NK cells express cytoplasm granules containing cytolytic effector molecules (as perforins, studied here) which can recognize and destroy damaged, infected and/or mutated target cells. To investigate whether an altered distribution of perforins in cytolytic cells or a reduced number of cytolytic cells producing perforins underlies decreased cytolytic activity with advancing age, perforin expression was assessed at the single cell level in T- (CD4 and CD8) and NK (CD16) peripheral blood lymphocytes from elderly subjects by flow cytometry. Perforin distribution at the cellular level in CD8+ and CD16+ cell cytoplasm suggested a similar distribution during ageing and a similar number of cells producing perforins. In addition, perforin utilization was maintained in the generation of cytolytic activity against K562 target cells and perforin synthesis in culture following activation was unabated. These data stress the importance of other factors, such as defective signal transduction for granule exocytosis, that may account for the different pattern of lytic activity found in aged people.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9080399     DOI: 10.1016/s0047-6374(96)01829-5

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  13 in total

1.  Change in perforin-positive peripheral blood lymphocyte (PBL) subpopulations following exercise.

Authors:  R Staats; S Balkow; S Sorichter; H Northoff; H Matthys; W Luttmann; A Berg; J C Virchow
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

2.  Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.

Authors:  Adrian J Reber; Tatiana Chirkova; Jin Hyang Kim; Weiping Cao; Renata Biber; David K Shay; Suryaprakash Sambhara
Journal:  Aging Dis       Date:  2011-09-30       Impact factor: 6.745

3.  Reciprocal age related change in natural killer cell receptors for MHC class I.

Authors:  Charles T Lutz; Mikel B Moore; Sarah Bradley; Brent J Shelton; Susan K Lutgendorf
Journal:  Mech Ageing Dev       Date:  2005-02-19       Impact factor: 5.432

4.  Altered Th1/Th2 commitment in human CD4+ T cells with ageing.

Authors:  S Sakata-Kaneko; Y Wakatsuki; Y Matsunaga; T Usui; T Kita
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

5.  Aging of the Innate Immune System: An Update.

Authors:  Shegufta Mahbub; Aleah L Brubaker; Elizabeth J Kovacs
Journal:  Curr Immunol Rev       Date:  2011-02-01

Review 6.  NK and NKT cells in aging and longevity: role of zinc and metallothioneins.

Authors:  Eugenio Mocchegiani; Robertina Giacconi; Catia Cipriano; Marco Malavolta
Journal:  J Clin Immunol       Date:  2009-05-01       Impact factor: 8.317

7.  Perforin and resistance to SARS coronavirus 2.

Authors:  Louise Cunningham; Peter Simmonds; Ian Kimber; David Arthur Basketter; John Paul McFadden
Journal:  J Allergy Clin Immunol       Date:  2020-05-15       Impact factor: 10.793

Review 8.  NK cells in healthy aging and age-associated diseases.

Authors:  Xavier Camous; Alejandra Pera; Rafael Solana; Anis Larbi
Journal:  J Biomed Biotechnol       Date:  2012-11-20

9.  The impact of ageing on natural killer cell function and potential consequences for health in older adults.

Authors:  Jon Hazeldine; Janet M Lord
Journal:  Ageing Res Rev       Date:  2013-05-06       Impact factor: 10.895

10.  Biobran/MGN-3, an arabinoxylan rice bran, enhances NK cell activity in geriatric subjects: A randomized, double-blind, placebo-controlled clinical trial.

Authors:  Ahmed F Elsaid; Magda Shaheen; Mamdooh Ghoneum
Journal:  Exp Ther Med       Date:  2018-01-08       Impact factor: 2.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.